Avidity Biosciences Inc

Stock Chart, Company Information, and Scan Results

$41.04(as of Sep 11, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Avidity Biosciences Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$41.04
Ticker SymbolRNA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees391
CountyUSA
Market Cap$5,969.5M
EBIDTA-518.7M
10-Day Moving Average47.09
P/E Ratio-11.67
20-Day Moving Average46.37
Forward P/E Ratio0.00
50-Day Moving Average40.23
Earnings per Share-3.56
200-Day Moving Average33.64
Profit Margin-4,089.29%
RSI40.29
Shares Outstanding128.7M
ATR2.95
52-Week High56.00
Volume11,324,065
52-Week Low21.51
Most Recent Support Level45.88
Book Value1,192.7M
Most Recent Resistance Level49.16
P/B Ratio4.46
Upper Keltner53.02
P/S Ratio495.82
Lower Keltner39.73
Debt-to-Equity Ratio53.02
Next Earnings Date11/11/2025
Cash Surplus108.8M
Next Ex-Dividend DateUnknown

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Inc In Our Stock Scanner

As of Sep 12, 2025
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.